Compagnie Lombard Odier SCmA’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,727	Closed	-$86K	–	691
2017 Q4	$86K	Buy	+10,727	New	+$100K	﹤0.01%	498
2017 Q2	–	Sell	-826	Closed	-$20K	–	775
2017 Q1	$20K	Buy	+826	New	+$20.7K	﹤0.01%	638

Other funds holding MACK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Compagnie Lombard Odier SCmA's MACK Position: Q1 2018 in Review

Compagnie Lombard Odier SCmA sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q1 2018, closing a stake of 10,727 shares — an estimated $86K sold.

Compagnie Lombard Odier SCmA first reported a position in MACK in Q1 2017 and held it in 2 quarters. The position peaked at $86K in Q4 2017. 81 funds tracked by Wall St. Rank hold MACK as of Q1 2018.

Compagnie Lombard Odier SCmA reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
Compagnie Lombard Odier SCmA sold 10,727 Merrimack Pharmaceuticals, Inc. shares in Q1 2018, an estimated $86K.
Compagnie Lombard Odier SCmA first reported a position in Merrimack Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
Compagnie Lombard Odier SCmA's Merrimack Pharmaceuticals, Inc. position peaked at $86K in Q4 2017.
81 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2018.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2018, filed 11 May 2018.